Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin

被引:0
作者
Pedro Mezquita Raya
Antonio Pérez
Antonio Ramírez de Arellano
Teresa Briones
Barnaby Hunt
William J. Valentine
机构
[1] Clinica San Pedro,
[2] Hospital Torrecardenas,undefined
[3] Hospital de la Santa Creu i Sant Pau,undefined
[4] Novo Nordisk,undefined
[5] Ossian Health Economics and Communications,undefined
来源
Diabetes Therapy | 2013年 / 4卷
关键词
Cost; Cost-effectiveness; DPP-4; GLP-1; Incretin; Liraglutide; Sitagliptin; Spain; Type 2 diabetes;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:417 / 430
页数:13
相关论文
共 111 条
[1]  
Soriguer F(2012)Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bete.es study Diabetologia 55 88-93
[2]  
Goday A(2010)Global healthcare expenditure on diabetes for 2010 and 2030 Diabetes Res Clin Pract 87 293-301
[3]  
Bosch-Comas A(2003)Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 383-393
[4]  
Zhang P(2008)Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 580-591
[5]  
Zhang X(2008)Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study Diabetes Care 31 1510-1515
[6]  
Brown J(2006)Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 29 1963-1972
[7]  
Gaede P(2006)The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 1696-1705
[8]  
Vedel P(2010)Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial Lancet 375 1447-1456
[9]  
Larsen N(2004)The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making Curr Med Res Opin 20 5-26
[10]  
Jensen GV(2004)Validation of the CORE Diabetes Model against epidemiological and clinical studies Curr Med Res Opin 20 27-40